CLINICAL TRIALS PROFILE FOR ESTERIFIED ESTROGENS

All Clinical Trials for ESTERIFIED ESTROGENS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00141544 ↗	The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women	Terminated	Solvay Pharmaceuticals	Phase 2	2004-07-01	To determine whether treatment with ESTRATEST® Tablets is superior to treatment with esterified estrogens tablets
NCT00141557 ↗	The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women	Terminated	Solvay Pharmaceuticals	Phase 2	2004-07-01	To determine whether treatment with ESTRATEST® Tablets is superior to treatment with esterified estrogens tablets
NCT00141570 ↗	Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women	Completed	Solvay Pharmaceuticals	Phase 2	2004-06-01	To determine whether treatment with ESTRATEST® H.S. Tablets is superior to treatment with esterified estrogens tablets
NCT00160342 ↗	Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes	Completed	Solvay Pharmaceuticals	Phase 2	2005-06-01	This is a research study to evaluate the effectiveness, safety and side effects of several dose levels of esterified estrogens (EE) and methyltestosterone (MT) given individually and in combination compared to a placebo (a tablet with no active drug in it) as a possible treatment for vasomotor symptoms (such as hot flushes and flushing) of menopause. EE and testosterone are two hormones which are typically deficient in menopausal women
NCT00357006 ↗	A Definitive Estrogen Patch Study (ADEPT)	Completed	Stanley Medical Research Institute	Phase 2	2006-07-01	OBJECTIVE: To test the use of adjunctive estrogen in a 8 week, three-arm, double-blind, placebo-controlled study in the treatment of psychotic symptoms in women with schizophrenia. HYPOTHESIS: That women receiving adjunctive estrogen will demonstrate significantly greater improvements in the symptoms of schizophrenia than women receiving adjunctive placebo. STUDY POPULATION: 180 women will be recruited over a three-year period across three sites. Participant will be of potential child-bearing age (Pre-menopausal and Post-menarche) with a current diagnosis of Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder (not in manic phase)according to the Mini International Neuropsychiatric Interview (MINI). STUDY MEDICATION: Estradiol. One third of the participants (n=60) will be randomised to receive adjunctive 100mcg Estradiol; one third of the participants (n=60) will be randomised to receive adjunctive 200mcg Estradiol n=60; and, one third of the participants (n=60) will be randomised to receive adjunctive placebo n=60). All patches will be covered with identical adhesive contact to ensure the "blind" is maintained. STUDY EVALUATIONS: Data will be collected over a two-month period for each participant. Visits will be performed at baseline, and then at weekly or fortnightly intervals. A total of six visits will be completed for each participant. The following evaluations will be performed: i) Inclusion/exclusion checklist. (Baseline visit only) ii) Informed consent. (Baseline visit only) iii)psychiatric evaluation to determine diagnosis. (Baseline visit only) iv) General clinical evaluation including medical history, current conditions and a non-invasive physical examination, body weight, vital signs. (Baseline and endpoint visits) v) Medication history. (Baseline and evaluation visits) vi) Demographics. (Baseline visits only) vii) The primary outcome measures will be the Positive and Negative Syndrome Scale (PANSS), which will be taken at weeks 1, 2, 4 and 8 of the trial. Cognitive testing will take place at baseline and 8 weeks. Side effects will be assessed at weeks 1, 2, 4, 6, and 8 to measure changes in subject's reported side effects during the trial. viii) Laboratory tests including; Serum levels of mood stabiliser, LH, FSH, Estrogen, Progesterone, Prolactin, DHEA,Testosterone and(Baseline and evaluation visits).

Clinical Trial Conditions for ESTERIFIED ESTROGENS

Condition Name

Condition Name for ESTERIFIED ESTROGENS
Intervention	Trials
Menopause	3
Schizophreniform Disorder(Not in Manic Phase)	1
Hot Flushes, Menopause, Postmenopause	1
Schizoaffective Disorder	1

Condition MeSH

Condition MeSH for ESTERIFIED ESTROGENS
Intervention	Trials
Schizophrenia	1
Psychotic Disorders	1
Disease	1
Hot Flashes	1

Clinical Trial Locations for ESTERIFIED ESTROGENS

Trials by Country

Trials by Country for ESTERIFIED ESTROGENS
Location	Trials
United States	118
Canada	5
Russian Federation	1
Australia	1

Trials by US State

Trials by US State for ESTERIFIED ESTROGENS
Location	Trials
South Carolina	4
Pennsylvania	4
Oregon	4
Oklahoma	4
Ohio	4

Clinical Trial Progress for ESTERIFIED ESTROGENS

Clinical Trial Phase

Clinical Trial Phase for ESTERIFIED ESTROGENS
Clinical Trial Phase	Trials
Phase 2	5

Clinical Trial Status

Clinical Trial Status for ESTERIFIED ESTROGENS
Clinical Trial Phase	Trials
Completed	3
Terminated	2

Clinical Trial Sponsors for ESTERIFIED ESTROGENS

Sponsor Name

Sponsor Name for ESTERIFIED ESTROGENS
Sponsor	Trials
Solvay Pharmaceuticals	4
Stanley Medical Research Institute	1
The Alfred	1

Sponsor Type

Sponsor Type for ESTERIFIED ESTROGENS
Sponsor	Trials
Industry	4
Other	2

Esterified Estrogens: Clinical Trial Updates, Market Analysis, and Projection

Last updated: May 3, 2026

What is the current clinical development picture for esterified estrogens?

Esterified estrogens (commonly marketed as esterified estrogens, USP in combination with progestin for endometrial protection in women with an intact uterus) are not supported by a sustained, new-build global pipeline of late-stage clinical trials in major registries in recent years. The dominant commercial reality is that esterified estrogens behave as an established hormone therapy product class with post-marketing safety labeling evolution rather than active late-stage development for new indications.

Clinical trial activity signal (what matters for pipeline risk)

For business and investment positioning, the key question is whether new data are likely to drive uptake via label expansion, new formulations, or conversion to differentiated regimens (once-daily implants, novel delivery systems, or new endpoints).

Across recent registry trends, esterified estrogens show:

• Low visibility of large, late-stage interventional trials generating label-expansion evidence in major indications (vasomotor symptoms, prevention of osteoporosis in postmenopausal women, hypoestrogenism).
• Ongoing smaller observational or safety-oriented studies that tend not to create new commercial differentiation at scale.

Bottom line: esterified estrogens compete on pricing, access, and supply, not on new clinical differentiation.

Which ongoing evidence themes drive labeling and clinical practice for esterified estrogens?

Esterified estrogens are part of systemic estrogen therapy. Current clinical practice uses labeling-constrained risk framing built on:

• Cardiovascular and thromboembolic risk stratification
• Breast cancer risk considerations
• Endometrial hyperplasia and cancer risk in women with a uterus unless a progestin is used
• Timing hypothesis language (risk differs by baseline factors and time since menopause)

These themes persist in prescribing behavior because systemic estrogens drive core class risks. Where new “updates” appear, they typically come through:

• Safety review updates
• Regimen adherence guidance
• Progestin use reinforcement

What is the market structure for esterified estrogens?

The market for esterified estrogens is best modeled as a subset of systemic estrogen hormone therapy and is characterized by:

• Generic and branded substitution
• Therapy switching based on formulary placement
• Progestin combination requirements for uterine protection
• Sustained but mature demand tied to menopause prevalence and health plan coverage

Demand drivers

• Postmenopausal population and menopause transition prevalence
• Persistence of menopausal symptom management needs
• Coverage and formulary inclusion for estrogen-progestin combinations
• Clinician prescribing comfort and patient tolerability

Supply and payer dynamics

• Brands tend to face generic competition.
• Uptake often correlates with formularies, not trial breakthroughs.
• Short-cycle demand is sensitive to drug availability and reimbursement policy.

Where does esterified estrogens sit relative to competing systemic estrogen classes?

Esterified estrogens compete with:

• Other oral conjugated estrogens products and generics
• Transdermal estrogen products (often promoted for lower thromboembolic risk)
• Intravaginal and local therapies for symptom subsets (less directly substitutable for systemic indications)

Relative positioning:

• Oral systemic estrogen remains widely used.
• Transdermal products increasingly gain share in some payer frameworks due to perceived safety profiles, especially in higher-risk patient segments.
• Esterified estrogens can still win where oral regimens are preferred and where payer economics favor generics.

What is the competitive and regulatory reality affecting forecasted share?

For systemic estrogens, regulatory outcomes do not typically hinge on new efficacy trials alone. Forecasting must account for:

• Existing class labeling
• Ongoing safety data interpretation
• Risk mitigation (progestin pairing, dose minimization)
• Post-market surveillance expectations

Practical commercialization constraint

Even when a company can produce incremental clinical evidence, the ceiling for label expansion can be limited because:

• Core risk statements remain class-driven.
• Payers may not reclassify risk fast enough to justify major switching unless safety data materially change risk perception.

How should a market projection be built for esterified estrogens?

A credible projection model for esterified estrogens should be built on a mature-market approach:

1. Base demand anchored to menopause prevalence and systemic HRT penetration
2. Switching rates between oral and transdermal/systemic alternatives
3. Formulary and reimbursement drift by payer tier placement
4. Generic pricing erosion and competitive entry timelines
5. Safety labeling impact on prescribing behavior (incremental but persistent)

Projection structure (directional)

Given mature status and likely absence of major new late-stage evidence:

• Volume: stable to modestly down over a multi-year horizon in markets where transdermal share rises.
• Price: down due to generic competition unless protected by formulation or distribution.
• Revenue: typically constrained by both volume migration and price erosion, with occasional rebounds driven by supply or formulary changes.

What is the likely 3-to-5 year outlook (commercial, not exploratory)?

Base case (most probable)

• Sales drift follows generic pricing pressure and gradual share migration toward transdermal estrogen regimens.
• Patient adherence remains a stabilizer because systemic oral estrogen regimens often have entrenched prescribing patterns and patient routine use.

Bull case (what would lift the curve)

• Sustained formulary coverage in large payer systems.
• Supply stability that prevents substitution to alternative products.
• Narrow improvements in risk framing that support clinician confidence (usually labeling updates rather than new approvals).

Bear case (what would drag the curve)

• Rapid shift toward transdermal estrogen products in formulary design.
• Intensified restrictions in higher-risk cohorts.
• Price compression accelerating due to more generic entrants or deeper rebate pressure.

What clinical trial events would be commercially “material” for esterified estrogens?

For this asset class, material events are those that change:

• Indication scope (new endpoints or eligibility)
• Regimen structure (new progestin pairing or delivery)
• Safety narrative in a way that changes payer coverage decisions

In absence of late-stage label expansion trials, forecast confidence should sit on market mechanics rather than clinical breakthroughs.

Key Takeaways

• Esterified estrogens show low evidence of a new, late-stage clinical pipeline driving label expansion; the commercial story is mature-market maintenance rather than differentiation through trials.
• Market demand is sustained by menopause prevalence and systemic HRT use, but oral systemic estrogens face ongoing share pressure from transdermal options.
• Revenue outlook is likely dominated by generic price erosion, formulary dynamics, and substitution behavior rather than major clinical trial inflection points.
• Forecasting should emphasize payer placement, rebate economics, and switching rates, not new efficacy differentiation.

FAQs

1. Are there recent late-stage trial results that could expand indications for esterified estrogens?
   No meaningful late-stage label-expansion signal drives a new differentiation narrative in recent registry-visible activity.

2. What endpoints would matter most if new trials are run?
   Safety endpoints tied to cardiovascular, thromboembolic, and breast cancer risk, plus endometrial protection outcomes in uterine-intact women.

3. Why does progestin pairing dominate clinical use?
   It reduces endometrial hyperplasia and cancer risk in women with a uterus receiving systemic estrogen.

4. What changes would improve commercial performance most?
   Sustained formulary coverage, stable supply, and reimbursement conditions that reduce substitution to transdermal alternatives.

5. How should investors model risk for esterified estrogens?
   Base forecasts on mature utilization, generic pricing, and payer-driven switching rather than assuming clinical trial-driven label growth.

References

[1] U.S. Food and Drug Administration. Drug Safety Communication and labeling information for estrogen-containing products (systemic). https://www.fda.gov/drugs/drug-safety-and-availability
[2] ClinicalTrials.gov. Search results for “esterified estrogens” (trial activity and study types). https://clinicaltrials.gov/